How to buy Viatris stock (MYL)

Viatris is a drug manufacturers - specialty & generic business based in the US. Viatris shares (MYL) are listed on the NASDAQ and all prices are listed in US Dollars. Viatris employs 35,000 staff and has a trailing 12-month revenue of around $11.5 billion.

Our top picks for where to buy Viatris stock

Buy Viatris stock from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.

Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.

Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.

Viatris stock price (NASDAQ: MYL)

Use our graph to track the performance of MYL stocks over time.

Viatris shares at a glance

• Key figures

Information last updated 2024-06-30.

52-week range	$0.00 - $0.00
50-day moving average more info button	$16.42
200-day moving average more info button	$16.12
Wall St. target price	$21.75
PE ratio more info button	30.7267
Dividend yield more info button	N/A
Earnings per share (TTM) more info button	$0.52

Is it a good time to buy Viatris stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Is Viatris stock undervalued or overvalued?

Valuing Viatris stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Viatris's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Viatris's P/E ratio

Viatris's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 31x. In other words, Viatris shares trade at around 31x recent earnings.

That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.

Viatris's PEG ratio

Viatris's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 1.59. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.

The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Viatris's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.

Viatris's EBITDA

Viatris's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $3.5 billion.

The EBITDA is a measure of a Viatris's overall financial performance and is widely used to measure a its profitability.

Viatris financials

Revenue TTM	$11.5 billion
Operating margin TTM	15.72%
Gross profit TTM	$4.6 billion
Return on assets TTM	3.63%
Return on equity TTM	0%
Profit margin	2.31%
Book value	$24.27
Market Capitalization more info button	$8.6 billion

TTM: trailing 12 months

Viatris share dividends

We're not expecting Viatris to pay a dividend over the next 12 months.

Have Viatris's shares ever split?

Viatris's shares were split on a 3:2 basis on 8 October 2003 . So if you had owned 2 shares the day before before the split, the next day you'd have owned 3 shares. This wouldn't directly have changed the overall worth of your Viatris shares – just the quantity. However, indirectly, the new 33.3% lower share price could have impacted the market appetite for Viatris shares which in turn could have impacted Viatris's share price.

Viatris share price volatility

Over the last 12 months, Viatris's shares have ranged in value from as little as $0 up to $0. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Viatris's is 1.4656. This would suggest that Viatris's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Viatris overview

Mylan N. V. , together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic, branded-generic, brand-name, and over-the-counter (OTC) pharmaceutical products in North America, Europe, and internationally. It offers active pharmaceutical ingredients and finished dosage forms; and antiretroviral medicines to treat HIV/AIDS. The company also provides prescription products, such as EpiPen Auto-Injector; Perforomist Inhalation Solution; Dymista; Creon; and Influvac, as well as YUPELRI, an inhalation solution for the maintenance treatment of patients with chronic obstructive pulmonary diseases. In addition, it markets OTC products, including Cold-EEZE, MidNite, Vivarin, Brufen, CB12, and EndWarts. The company offers its products to therapeutic areas, such as cardiovascular, CNS and anesthesia, dermatology, diabetes and metabolism, gastroenterology, immunology, infectious disease, oncology, respiratory and allergy, and women's health.

Frequently asked questions

What percentage of Viatris is owned by insiders or institutions?
Currently 0.912% of Viatris shares are held by insiders and 90.496% by institutions. How many people work for Viatris?
Latest data suggests 35,000 work at Viatris. When does the fiscal year end for Viatris?
Viatris's fiscal year ends in December. Where is Viatris based?
Viatris's address is: Building 4, Hatfield, United Kingdom, AL10 9UL What is Viatris's ISIN number?
Viatris's international securities identification number is: USN594651093 What is Viatris's CUSIP number?
Viatris's Committee on Uniform Securities Identification Procedures number is: 628530107